ACR Meeting Abstracts

ACR Meeting Abstracts

  • Home
  • Meetings Archive
    • ACR Convergence 2022
    • ACR Convergence 2021
    • ACR Convergence 2020
    • 2020 ACR/ARP PRSYM
    • 2019 ACR/ARP Annual Meeting
    • 2018 ACR/ARHP Annual Meeting
    • 2017-2009 Meetings
    • Download Abstracts
  • Keyword Index
  • Advanced Search
  • Your Favorites
    • Favorites
    • Login
    • View and print all favorites
    • Clear all your favorites
  • Meeting Resource Center

Abstract Number: 1680

Higher Baseline Monocyte Count Is Associated with More Extensive Skin Involvement and Higher Mortality in Systemic Sclerosis

Vishnu Mohan1, Purvesh Khatri2, Samuel Theodore1, Julio Charles1, Hau Pham1, Deepthi Nair1, Madeleine Scott2, John D. Reveille1, Maureen D. Mayes1 and Shervin Assassi1, 1University of Texas McGovern Medical School, Houston, TX, 2Stanford University, Stanford, CA

Meeting: 2017 ACR/ARHP Annual Meeting

Date of first publication: September 18, 2017

Keywords: monocytes, Scleroderma, skin fibrosis and systemic sclerosis

  • Tweet
  • Email
  • Print
Session Information

Date: Monday, November 6, 2017

Session Title: Systemic Sclerosis, Fibrosing Syndromes and Raynaud's – Clinical Aspects and Therapeutics Poster II

Session Type: ACR Poster Session B

Session Time: 9:00AM-11:00AM

Background/Purpose:

Macrophages are the primary inflammatory cell type present in the systemic sclerosis (SSc) skin. Circulating monocytes can give rise to profibrotic inflammatory cells such as alternatively activated macrophages in the fibrotic end-organ such as skin and lung. Despite their importance, there are no previous studies examining the clinical correlates of peripheral blood monocyte count in SSc. The primary objective of the present study was to examine the association of monocyte count with clinical variables and survival in the prospective Genetics Versus Environment In Scleroderma Outcome Study (GENISOS) cohort.

Methods:

Monocyte count was prospectively obtained at enrollment in 429 patients. All patients had disease duration less than 5 years (from the first non-Raynaud’s phenomenon symptom) and fulfilled the 2013 ACR/EULAR criteria. Modified Rodnan Skin Score (mRSS) and forced vital capacity % predicted (FVC%) were also obtained prospectively. SSc related autoantibodies were determined in the divisional laboratory using gold standard methods. After mean follow-up of 8.3 years, 129 patients had died.

Results:

The mean disease duration at enrollment was 2.4 years and the majority of patients had diffuse cutaneous involvement (60.4%). Higher monocyte count was associated with diffuse cutaneous disease type (b=59.4, p=0.012). Furthermore, higher monocyte count was significantly associated with higher baseline mRSS (r=0.17, p=0.001) while there was no correlation with baseline FVC%. There was a trend for association of higher monocyte counts with RNA polymerase III positivity (b=55.2, p=0.055) while there was no association with other SSc-related autoantibodies. Higher monocyte count also correlated with lower disease duration at the baseline visit (r=-0.11, p=0.022)

In the multivariable cox regression analysis after adjustment for age at enrollment, monocyte count was associated with higher mortality (p=0.028). Next, patients were classified based on normal vs. high monocyte count as reported by the clinical laboratory. SSc patients with a high monocyte count had higher mortality even after adjustment for age and baseline mRSS (see Table).

Conclusion:

Higher peripheral blood monocyte count was associated with shorter disease duration, more extensive skin disease, and higher mortality. This study provides clinical support for relevance of monocytes and bone marrow derived macrophages in SSc pathogenesis.

Clinical Variable

Hazard ratio

95% CI

p-value

High monocyte count at enrollment

2.65

1.07 – 6.57

0.035

Age at enrollment

1.02

1.01 – 1.04

0.003

mRSS at enrollment

1.01

0.99 – 1.02

0.243


Disclosure: V. Mohan, None; P. Khatri, None; S. Theodore, None; J. Charles, None; H. Pham, None; D. Nair, None; M. Scott, None; J. D. Reveille, None; M. D. Mayes, None; S. Assassi, Bayer Healthcare, 2,Biogen Idec, 2,Reata, 5,Boehringer Ingelheim, 5.

To cite this abstract in AMA style:

Mohan V, Khatri P, Theodore S, Charles J, Pham H, Nair D, Scott M, Reveille JD, Mayes MD, Assassi S. Higher Baseline Monocyte Count Is Associated with More Extensive Skin Involvement and Higher Mortality in Systemic Sclerosis [abstract]. Arthritis Rheumatol. 2017; 69 (suppl 10). https://acrabstracts.org/abstract/higher-baseline-monocyte-count-is-associated-with-more-extensive-skin-involvement-and-higher-mortality-in-systemic-sclerosis/. Accessed February 3, 2023.
  • Tweet
  • Email
  • Print

« Back to 2017 ACR/ARHP Annual Meeting

ACR Meeting Abstracts - https://acrabstracts.org/abstract/higher-baseline-monocyte-count-is-associated-with-more-extensive-skin-involvement-and-higher-mortality-in-systemic-sclerosis/

Advanced Search

Your Favorites

You can save and print a list of your favorite abstracts during your browser session by clicking the “Favorite” button at the bottom of any abstract. View your favorites »

ACR Pediatric Rheumatology Symposium 2020

© COPYRIGHT 2023 AMERICAN COLLEGE OF RHEUMATOLOGY

Wiley

  • Home
  • Meetings Archive
  • Advanced Search
  • Meeting Resource Center
  • Online Journal
  • Privacy Policy
  • Permissions Policies
  • Cookie Preferences